Send to:

Choose Destination
See comment in PubMed Commons below
Endoscopy. 2014 Jan;46(1):59-65. doi: 10.1055/s-0033-1358803. Epub 2013 Nov 19.

Long-term outcome of capsule endoscopy in obscure gastrointestinal bleeding: a nationwide analysis.

Author information

  • 1Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • 2Seoul St. Mary's Hospital, College of Medicine, The Catholic University, Seoul, Korea.
  • 3Kyungpook National University Hospital, Daegu, Korea.
  • 4Korea University Hospital, Seoul, Korea.
  • 5Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
  • 6Yoido St. Mary's Hospital, College of Medicine, The Catholic University, Seoul, Korea.
  • 7University of Soonchunhyang, Seoul, Korea.
  • 8Department of Gastroenterology, Ajou University Hospital, Ajou University School of Medicine, Suwon, Korea.
  • 9University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
  • 10Ewha Womans University School of Medicine, Seoul, Korea.
  • 11Inje University Seoul Paik Hospital, Seoul, Korea.
  • 12Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
  • 13Yonsei University College of Medicine, Seoul, Korea.



The clinical impact of video capsule endoscopy (VCE) in patients with obscure gastrointestinal bleeding (OGIB) remains undetermined. The aim of this study was to evaluate the long-term clinical impact of VCE in patients with OGIB using a nationwide registry.


Data from 305 patients who underwent VCE for OGIB from 13 hospitals in Korea between January 2006 and March 2009 were analyzed. Prospectively collected VCE registry data were reviewed, and follow-up data were collected by chart review and telephone interviews with patients. Multivariate regression analyses using hazard ratios (HR) were performed to determine risk factors for rebleeding.


Significant findings were detected in 157 patients (51.5%). After VCE, interventional treatment was performed in 36 patients (11.8%). The overall rebleeding rate was 19.0% during a mean (±SD) follow-up of 38.7±26.4 months. Rebleeding rate did not differ by positive VCE results or application of interventional treatment. Multivariate analysis revealed that angiodysplasia (HR 1.82; 95% confidence interval [CI] 1.04-3.20; P=0.037) and duration of OGIB >3 months (HR 1.64; 95%CI 1.10-2.46; P=0.016) were independent prognostic factors associated with rebleeding. In a subgroup analysis of patients taking anticoagulants, patients who discontinued drugs after VCE showed a lower rebleeding rate than those who did not discontinue this therapy (P=0.019).


VCE did not have a significant impact on the long-term outcome of patients with OGIB. Patients with angiodysplasia on VCE or OGIB>3 months need to be closely followed even after interventional treatment. In patients who are taking anticoagulants, discontinuation of drugs is necessary in order to lower the risk of rebleeding.

© Georg Thieme Verlag KG Stuttgart · New York.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Georg Thieme Verlag Stuttgart, New York
    Loading ...
    Write to the Help Desk